The whole debate reduces to one unnamed acquisition the CFO has earmarked $390M–$650M for.

• The cash is the story. Net cash of $380M equals 30% of market cap; the headline 7.5% ROE is mechanically depressed by idle capital — the CFO states ROIC on an ex-cash business basis is already 9%+.
• Management has pre-committed to spending most of it. MTMP FY30 earmarks $390M–$650M for an unnamed fourth core business, on top of the three existing subsidiaries. No target has been announced; the Serato DJ-software deal was blocked by regulators in 2024, and JLab took a $40M goodwill write-down inside 18 months of its 2021 close.
• A $650M deal at 2.0× sales on a 10%-EBITDA-margin target wipes out roughly $260M of equity value on day one. A disciplined sub-$200M adjacent deal at ≤1.0× sales is the bull case; anything larger or outside core competence is the bear's primary trigger.

Record earnings, pristine balance sheet, 13× P/E — the multiple compressed while earnings power expanded.

The turnaround is real: revenue has printed eleven consecutive quarters of year-over-year growth, operating margin stepped from the 4–6% band to 18%, and FY2024 produced $196M of free cash flow at 188% conversion of net income. The balance sheet is the strongest since 2008 — net cash $380M, Altman Z 3.5, Piotroski 8/9. What has to hold over the next twelve months: audio gross margin through the new tariff regime, and operating margin staying above 16% on the August-2026 H1 print.

FY2025 grew the top line 12% — and net income fell 3%. The plateau arrived.

• Margin squeeze, not headline miss. FY2025 revenue rose to $770M from $710M, but net income slipped from $104M to $101M. Management cut guidance on May 9, 2025 to absorb the direct US-tariff and FX hit — revenue $728M → $715M, operating profit down ~8% — and explicitly declined to model further demand destruction.
• Capital return pivoted toward buybacks. Feb 13, 2026 authorized a $19M / 1.6M-share repurchase (first real buyback in years) and re-based the ordinary dividend to $0.24/share post-split. A second tranche update landed April 2, 2026 — the family anchor is signaling capital return over further M&A.
• Risk register rewrote itself. US-tariff prominence jumped from 1/10 in FY22 to 10/10 in FY25; M&A-integration risk from 5 to 9. The cleanup-era risk factors (supply chain, JLab goodwill, healthcare exit) all faded — replaced by a pair of risks tied to one variable: capital deployment.

Non-family CEO with $26M personally at risk, 47.5% family anchor that has so far chosen value-unlock over extraction.

• Iwakiri, CEO since June 2018. Installed after the family-era diversification bets underperformed; personally owns 1.74% of the company (~$26M) — unusually high for a non-founder Japanese CEO. Sold the JMDC healthcare stake to Omron for $710M, exited Halmek and Doctor-NET, and hit MTMP FY25 one year early after already having hit it two years early.
• Nishimoto family owns ~47.5% through Nishimoto Kosan + Kayo Nishimoto. De-facto control at any AGM, yet no seat on the board. Since 2018 the family has backed every value-unlock — JMDC divestiture, 3-for-1 split in July 2025, the February 2026 buyback — with zero disclosed related-party transactions.
• Governance grades B+, not A. Board is 4-of-6 independent with a CPA-chaired audit committee and attorney-chaired nominations; ISS QualityScore 1 (best), MSCI AA. Two structural weaknesses: the audit chair just crossed Noritsu's own 10-year independence ceiling, and the CEO still sets his own bonus within the committee-approved band.